Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The prospective pravastatin pooling project

Circulation

Volumn 102, Issue 16, 2000, Pages 1893-1900

  Sacks, Frank M ^a,b,c   Tonkin, Andrew M ^d   Shepherd, James ^e   Braunwald, Eugene ^a,b   Cobbe, Stuart ^e   Hawkins, C Morton ^f   Keech, Anthony ^g   Packard, Christopher ^e   Simes, John ^g   Byington, Robert ^h   Furberg, Curt D ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h WAKE FOREST UNIVERSITY   (United States)

Author keywords

Coronary disease; Drugs; Lipids; Lipoproteins; Meta analysis

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0034680352     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.16.1893     Document Type: Article

References (14)

1. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
2. Prevention of cardiovascular events and the deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
4. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) Project
5. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid
6. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
7. Detailed diagnoses and procedures
8. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
9. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial
10. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
11. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
12. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials